Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy

Keyphrases

• Tumor Immunity 100%
• Tumor Immunotherapy 100%
• Effector T Cells 100%
• T Cell Exhaustion 100%
• T Cell Senescence 100%
• Regulatory T Cells 45%
• Mitogen-activated Protein Kinase 27%
• Tumor 27%
• Tumor Cells 27%
• T Cells 27%
• Breast Cancer 27%
• Tumor Microenvironment 27%
• Mouse Tumor 27%
• Ataxia Telangiectasia mutated 27%
• DNA Damage 18%
• Lung Cancer 18%
• Tumor Model 18%
• Cancer Immunotherapy 18%
• Melanoma 18%
• Tumor-specific T Cells 18%
• Anti-programmed Death 1 18%
• Senescent T Cells 18%
• Knock-in Mouse Model 9%
• Molecular Mechanism 9%
• Loss Function 9%
• Quantitative PCR 9%
• Cellular Senescence 9%
• Malignant Tumor 9%
• Malignant Cells 9%
• Flow Cytometry 9%
• Human Tumors 9%
• Multiplex Assay 9%
• Mouse Lung 9%
• Breast Tumor 9%
• Tumor Development 9%
• Effective Strategies 9%
• Pharmacological Inhibitors 9%
• Adoptive Transfer 9%
• Melanocytic Tumor 9%
• Functional State 9%
• Adoptive Cell Therapy 9%
• Multiple Markers 9%
• Blockage 9%
• Tumor-infiltrating T Cells 9%
• Histochemistry 9%
• Background Current 9%
• T Cell Subpopulations 9%
• Checkpoint Blockade 9%
• Dysfunctional States 9%
• Checkpoint Blockade Therapy 9%
• Melanoma Model 9%

Medicine and Dentistry

• Immunotherapy 100%
• T Cell 100%
• Cellular Senescence 100%
• Neoplasm 33%
• Tumor Cell 22%
• Regulatory T Cell 22%
• Melanoma 22%
• Kinase Signaling 16%
• Mitogen-Activated Protein Kinase 16%
• Tumor Microenvironment 16%
• Cancer Immunotherapy 16%
• ATM Protein 16%
• Malignant Neoplasm 11%
• DNA Damage 11%
• Lung Cancer 11%
• In Vitro 11%
• Breast Cancer 11%
• Tumor Model 11%
• Specific Tumor 11%
• Programmed Death 1 Ligand 1 11%
• Cancer 5%
• Cell Population 5%
• Flow Cytometry 5%
• Histochemistry 5%
• Cell Signaling Pathway 5%
• Cell Therapy 5%
• Real Time Polymerase Chain Reaction 5%
• Adoptive Transfer 5%